NCT02308241View on ClinicalTrials.gov

Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 2, 2014

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions
Human Papillomavirus (HPV)-Related MalignanciesRecurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Interventions
DRUG

Ribavirin

self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

07939

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02308241 - Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies | Biotech Hunter | Biotech Hunter